PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|November 2, 2019
- Pharmaceutical Technology-11-02-2019
- Volume 43
- Issue 11
Innomech Benchtop Systems
The new Innomech Benchtop Systems developed for and offered by Aston Particle Technologies (APT) combine two benchtop systems to organize small amounts of blended pharmaceutical powders for use in APT’s formulation development projects.
The new Innomech Benchtop Systems developed for and offered by Aston Particle Technologies (APT) combine two benchtop systems to organize small amounts of blended pharmaceutical powders for use in APT’s formulation development projects.
The system uses the company’s one-step particle engineering technology to prepare up to 10 grams of blended material while maintaining the same process technology, conditions, and recipe-based control system of APT’s two-kilogram pilot-scale production unit. Through its ability to produce small quantities for proof of principle studies, pharmaceutical companies have the option to buy in bulk quantities or to scale up its synthesis of specific ingredients.
Articles in this issue
almost 7 years ago
QbD Takes Shape for Topical Pharmaceuticalsalmost 7 years ago
Optimizing Compression Coating for Pulsatile Release Tabletsalmost 7 years ago
Advancing Transdermal Drug Deliveryalmost 7 years ago
The Emergence of Operational Technology as a Servicealmost 7 years ago
Residual Moisture Determination in Lyophilized Drug Productsalmost 7 years ago
Highest Shear Mixer Availablealmost 7 years ago
Powder Dosing Unitalmost 7 years ago
Automated Cotton Inserteralmost 7 years ago
The Right Pieces for a Quality Programalmost 7 years ago
More Consistent Drug Inspection System on HorizonRelated to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.